Phase 2 Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma (DLCL)

Trial Profile

Phase 2 Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma (DLCL)

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Diphenhydramine; Paracetamol; Potassium iodide
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Feb 2011 Planned end date changed from Aug 2007 to Aug 2011 as reported by ClinicalTrials.gov.
    • 18 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 13 Jul 2008 Corixa Corp reported as as trial sponsor by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top